Genius Biotherapeutics


Tel: +27 21 427 1400
Fax: +27 21 419 0731

Genius Biotherapeutics (formerly Bioclones (Pty) Ltd)

Established in 1982, Genius Biotherapeutics is arguably the oldest healthcare biotechnology company in South Africa, if not the African continent. It has been in existence for well over 30 years and has a track record of investing in the research and development work that led to successfully commercialising South Africa’s first bio-similar product Repotin, a recombinant human hormone known as erythropoietin (EPO). Genius Biotherapeutics has made significant strides in the international scientific biotechnology community with three of its products being rated in the top ten by a prominent international publication. Genius Biotherapeutics has a strong pipeline of patent-protected technologies focused principally on the enhancement of cellular immune response in humans.

The group of companies runs the following business operations:

  • Manufacture and sale of Repotin
  • Development work in dendritic cell vaccine technology
  • Further developmental activities for granulocyte-colony stimulating factor (G-CSF) technology
  • Production of protein-based reagents